By Sheri Kasprzak
New York, Jan. 19 - Endo Pharmaceuticals Holdings Inc. priced a secondary public offering of its stock for $417.75 million.
Some of the company's shareholders will sell 15 million shares at $27.85 each, according to Bill Newbould, spokesman for Endo.
Citigroup Global Markets Inc. is the underwriter for the offering and has an over-allotment option for up to 2.25 million shares.
All of the shares being sold in the secondary offering are issued and outstanding except for 40,000 shares which represent outstanding stock options.
The shares will be sold under Endo's shelf registration.
Kelso & Co. is selling the majority of the shares.
Based in Chaddsford, Pa., Endo is a biopharmaceutical company focused on treatments for pain.
| Issuer: | Endo Pharmaceuticals Holdings Inc.
|
| Issue: | Stock
|
| Amount: | $417.75 million
|
| Shares: | 15 million
|
| Greenshoe: | For up to 2.25 million shares
|
| Price: | $27.85
|
| Warrants: | No
|
| Underwriter: | Citigroup Global Markets Inc.
|
| Pricing date: | Jan. 19
|
| Stock symbol: | Nasdaq: ENDP
|
| Stock price: | $28.15 at close Jan. 19
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
